If you or someone you love is managing type 2 diabetes, 2026 is turning out to be a genuinely exciting year in medicine. We are seeing real, meaningful breakthroughs, not just incremental tweaks to existing medications, but entirely new concepts in how we deliver and target blood sugar control. In fact, the current wave of innovation reflects a shift toward more personalized, patient friendly therapy rather than a one size fits all approach. As a pharmacist, I find myself explaining these updates to patients almost daily now, because the treatment landscape is shifting fast. Here’s what you need to know about the latest FDA approved medications for type 2 diabetes, broken down clearly, without the jargon. While these approvals are based on U.S. regulatory decisions, availability may vary depending on your country.
A Once Weekly Insulin? Yes, It’s Finally Real
Perhaps the biggest headline from 2026 is the arrival of Awiqli (insulin icodec-abae). According to a Novo Nordisk press announcement confirmed by the FDA on 26 March 2026, Awiqli became the first and only once weekly basal insulin approved for adults with type 2 diabetes. Let that sink in, after decades of patients injecting long-acting insulin every single day, we now have an option that only needs to be given once a week.
As reported in HCPLive following the approval, this makes insulin icodec the first new class of basal insulin to reach US patients in more than two decades. That’s not a small thing. For many people, the daily injection routine is genuinely exhausting and easy to slip on. Compliance suffers, and blood sugar control suffers with it.
So how does it work? According to the published prescribing information, Awiqli binds to serum albumin to form a depot in the body, which then gradually releases insulin icodec, providing a consistent glucose-lowering effect over the full one-week dosing interval. In simple terms, it acts like a slow, steady reservoir of insulin that maintains stable blood sugar levels throughout the week.
As noted in Drug Topics following the FDA decision, this approval potentially reduces the burden of basal insulin administration from 365 injections a year to just 52, and that number alone speaks volumes about what this means for quality of life.
The clinical evidence backing this is solid. According to the approval summary published in Consultant360, the FDA decision was supported by results from the ONWARDS phase 3 clinical programme, which included four randomised, active controlled, treat to target trials enrolling approximately 2,680 adults with uncontrolled type 2 diabetes. Across all four trials, researchers found that insulin icodec-abae met its primary endpoint of HbA1c reduction at week 52, proving non inferior to daily basal insulins, and in the ONWARDS 3 trial, published in JAMA in 2023, it was statistically superior to once-daily insulin degludec in adults with insulin-naïve type 2 diabetes. These findings suggest that less frequent dosing does not compromise efficacy, and may even improve outcomes in certain groups.
According to the FDA approved labelling, Awiqli can be used alongside mealtime insulin, oral antidiabetic agents, and GLP-1 receptor agonists, making it flexible enough to slot into many different treatment plans. It comes as a pre-filled FlexTouch pen and is dosed based on individual metabolic needs and blood glucose monitoring.
Worth knowing, the most commonly reported adverse effects include hypoglycaemia, injection site reactions, weight gain, and hypersensitivity reactions, similar to other basal insulins. As with any insulin therapy, careful dose titration and regular monitoring are essential, especially during the initial adjustment phase.
Semaglutide Gets a Major New Indication, Kidney Protection
Most people know semaglutide as the active ingredient in Ozempic and Rybelsus. But in January 2025, according to a regulatory update announced by Novo Nordisk, the FDA approved a new indication for semaglutide, specifically to help lower the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
This matters enormously. Diabetic kidney disease is one of the most common and serious complications of type 2 diabetes, and historically, options to slow it down were limited. It is also a leading cause of dialysis and long-term disability worldwide. Adding to this, a large cardiovascular outcomes trial examining oral semaglutide in high-risk patients with type 2 diabetes, published in The New England Journal of Medicine in 2025, reinforced just how wide-reaching the benefits of this drug class have become, showing meaningful reductions in major adverse cardiovascular events in patients at elevated risk.
Having a medication that can simultaneously manage blood sugar, support weight loss, and now protect the kidneys is a step forward that many clinicians have been waiting for. This kind of multi-system benefit is often referred to as “cardiorenal protection,” and it is rapidly becoming a key goal in diabetes management. For anyone with both type 2 diabetes and early-stage kidney disease, this is a conversation worth having with your prescriber.
SGLT2 Inhibitors (Now Available for Children Too)
One of the more under reported but genuinely important developments is the expansion of SGLT2 inhibitors into paediatric use. Type 2 diabetes in children and teenagers is rising, and according to research published in Frontiers in Endocrinology in 2025, youth onset type 2 diabetes differs from adult onset in its pathogenesis, progresses more rapidly, and is associated with a higher incidence of complications that appear earlier in life.
Dapagliflozin (Farxiga, AstraZeneca) received FDA approval to improve glycaemic control in children aged 10 years and older with type 2 diabetes, based on findings from the phase 3 T2NOW trial published in NEJM Evidence. In that trial, researchers found that dapagliflozin reduced HbA1c by 0.62 percentage points at 26 weeks compared to placebo, a clinically meaningful result in a population where treatment options had been extremely limited.
Similarly, empagliflozin (Jardiance) received FDA approval for children aged 10 and older, based on results from the DINAMO phase III trial. According to data published following that trial, empagliflozin reduced HbA1c by 0.8% compared with placebo at 26 weeks in young patients with inadequately controlled type 2 diabetes.
As highlighted in an FDA press release at the time of these approvals, prior to this the only oral therapy approved for children with type 2 diabetes was metformin, which was first authorized for paediatric use back in 2000. That’s a 20-year gap in innovation for a population where treatment options were desperately needed.
According to a StatPearls review updated in September 2025, canagliflozin, dapagliflozin, and empagliflozin are all now approved for paediatric patients aged 10 years and older, while ertugliflozin and bexagliflozin remain restricted to adults. These drugs work by prompting the kidneys to flush excess glucose out through the urine. In addition to lowering blood sugar, they may also provide modest weight and blood pressure benefits. While they are generally well tolerated, they can increase the risk of genital infections and, rarely, a condition called euglycaemic diabetic ketoacidosis, so awareness and monitoring are important, especially in younger patients.
A More Affordable Insulin Option, Langlara Approved
Not every breakthrough has to be an entirely new molecule. In April 2026, according to the FDA’s new drug approvals database on Drugs.com, Langlara (insulin glargine-aldy) was approved as a long-acting human insulin analog interchangeable biosimilar to Lantus, for the treatment of diabetes mellitus in both type 1 and type 2 patients.
Biosimilar insulins like Langlara matter because they drive competition in a market that has historically had serious affordability problems. An interchangeable classification means your pharmacist can typically substitute it directly at the pharmacy counter without requiring a new prescription from your doctor, simplifying access and potentially reducing out of pocket costs considerably for long term insulin users. This is particularly important in regions where insulin affordability remains a major barrier to consistent treatment.
What’s Coming Next (CagriSema on the Horizon)
Looking ahead, one of the most anticipated treatments in the type 2 diabetes and obesity space is CagriSema. According to a Novo Nordisk regulatory filing and reporting by Drug Discovery News in February 2026, CagriSema is a once weekly injectable that combines semaglutide with cagrilintide, an amylin analogue that mimics a natural hormone helping to reduce post meal glucose spikes and suppress appetite beyond what GLP-1 therapy achieves alone.
As reported by Drug Discovery News, CagriSema is being developed not only for obesity but also for type 2 diabetes and cardiovascular risk reduction, with an FDA decision expected in 2026. Early Phase 2 results, described in the same report, suggested weight loss outcomes that could push beyond what any currently approved therapy achieves, which is why clinicians and patients alike are watching this one closely.
If approved, CagriSema could represent the most powerful single injection therapy available for people managing both type 2 diabetes and significant obesity, and it would mark the first time a GLP-1 and amylin analogue combination has been approved anywhere in this class.
What This All Means in Practice
The thread running through all of these approvals is personalization the growing recognition that type 2 diabetes is not a one size fits-all condition. Some patients need better kidney protection. Some need to escape the burden of daily injections. Children need age-appropriate, evidence-backed options. And cost barriers deserve to be chipped away through biosimilar competition.
As a pharmacist, my advice is simple: if you haven’t reviewed your diabetes medications with your doctor or pharmacist in the last year, now is a good time. The options available in 2026 are genuinely more varied, more convenient, and in several cases more protective than what was available even two or three years ago. Whether you’re newly diagnosed or managing this condition long-term, there’s a real chance that something in this new wave of approvals is worth discussing for your individual situation.
FAQs
Q1. What is the newest FDA-approved medication for type 2 diabetes in 2026?
The most significant new approval in 2026 is Awiqli (insulin icodec-abae), the world’s first once-weekly basal insulin for adults with type 2 diabetes, approved by the FDA on 26 March 2026.
Q2. How does once-weekly insulin Awiqli work?
Awiqli binds to a protein in the blood called albumin, forming a depot that slowly releases insulin over seven days. This provides steady, consistent blood sugar control without the need for daily injections.
Q3. Are there new diabetes medications now available for children?
Yes, both dapagliflozin (Farxiga) and empagliflozin (Jardiance) are now FDA approved for children aged 10 and older with type 2 diabetes, offering the first new class of oral treatment options for young patients since metformin was approved over two decades ago.
Q4. Can semaglutide (Ozempic) now protect the kidneys?
In January 2025, the FDA approved a new indication for semaglutide specifically to reduce the risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes who also have chronic kidney disease.
Q5. What is a biosimilar insulin and why does it matter?
A biosimilar insulin is a highly similar version of an already approved branded insulin. When classified as interchangeable (as Langlara is), pharmacists can substitute it for the original brand directly at the dispensing stage, which can reduce costs significantly for patients on long-term insulin therapy.
Q6. What is CagriSema and when will it be available?
CagriSema is an investigational once-weekly injection from Novo Nordisk that combines semaglutide with cagrilintide (an amylin analogue). It is awaiting an FDA decision in 2026 and is being developed for type 2 diabetes, obesity, and cardiovascular risk reduction.
Disclaimer
This article is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before starting, stopping, or changing any medication. Individual suitability for these treatments depends on your full medical history, kidney function, age, and other factors only your healthcare provider can assess.
Call to Action
Stay Ahead of What’s New in Diabetes Care
If this article helped you understand what’s changing in type 2 diabetes treatment, there’s plenty more where that came from. At PharmaHealths, I break down the latest in medications, clinical research, and health science into plain, honest language, written from a pharmacist’s perspective, not a press release.
Explore more evidence-based health articles at pharmahealths.com
Has a question about a medication mentioned here, or want me to cover a specific diabetes topic next? Drop it in the comments, I read every one.
References
• Novo Nordisk. FDA approves Novo Nordisk’s Awiqli® (insulin icodec-abae), the first and only once-weekly basal insulin treatment for adults with type 2 diabetes. Press release. 26 March 2026. Available at: prnewswire.com
• Consultant360. FDA Approves Awiqli (Insulin Icodec-Abae) as Once Weekly Basal Insulin for Adults with Type 2 Diabetes. Published 27 March 2026.
• Drug Topics. FDA Approves First Weekly Basal Insulin for Adults with Type 2 Diabetes. Published 2026.
• HCPLive. FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes. Published 2026.
• Lingvay I, et al. Once weekly insulin icodec vs once daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA. 2023;330(3):228–237.
• Novo Nordisk. FDA approves new indication for semaglutide to lower risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Regulatory update. January 2025.
• McGuire DK, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. The New England Journal of Medicine. 2025.
• Castorani V, et al. Established and emerging use of sodium glucose cotransporter-2 inhibitors in pediatric population with type 2 diabetes: a case report and literature review. Frontiers in Endocrinology. 2025. doi:10.3389/fendo.2025.1629488
• Shehadeh N, Barrett T, Galassetti P, et al. Dapagliflozin or saxagliptin in pediatric type 2 diabetes. NEJM Evidence. 2023;2(12): EVIDoa2300210.
• AstraZeneca. Farxiga approved in the US for the treatment of pediatric type 2 diabetes. Press release. June 2024.
• Boehringer Ingelheim/Eli Lilly. FDA approves Jardiance® for children 10 years and older with type 2 diabetes. Press release. June 2023.
• Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport 2 (SGLT2) Inhibitors. StatPearls. Updated September 15, 2025. Treasure Island (FL): StatPearls Publishing.
• Drugs.com. FDA Approves Langlara (insulin glargine-aldy), an Interchangeable Biosimilar to Lantus. April 29, 2026.
• Drug Discovery News. Five drug approvals to watch in 2026. Published February 3, 2026.
• Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management. Press release. 2025.